A practical approach to, diagnosis, assessment and management of idiopathic intracranial hypertension

Susan P Mollan, Keira A Markey, James D Benzimra, Andrew Jacks, Tim D Matthews, Michael A Burdon, Alex J Sinclair

INTRODUCTION

Idiopathic intracranial hypertension (IIH) is becoming increasingly prevalent in line with the global epidemic of obesity. In the UK, 22.7% of people are obese (Body Mass Index >30 kg/m²), while obesity throughout the world has doubled since 1980. Clinicians’ attitudes to IIH vary: in our experience, only a minority of patients are at high risk of clinically serious underlying disease, the latter became inappropriate with awareness that this is not a benign condition, given the risk of visual loss and disabling chronic headaches. Pseudotumour cerebri is becoming increasingly popular as a term to encompass primary raised intracranial pressure where there is no identifiable cause—which we term IIH—and secondary causes of raised pressure.

The diagnostic criteria of IIH are well known and have evolved since Dandy’s initial description in 1937; they include a CSF opening pressure of ≥25 cm H₂O (box 1). However, these criteria recommend imaging only to exclude a venous sinus thrombosis in patients without the typical IIH phenotype (obesity and female sex). We feel, however, that it is essential to exclude venous sinus thrombosis (using MRI or CT with venography) in all patients presenting with pseudotumour cerebri, since being female and obese does not preclude the diagnosis of venous sinus thrombosis. The diagnosis can be difficult and the consequences of error can lead either to the neglect of a serious treatable cause of raised intracranial pressure, blindness or inappropriate treatment of patients who do not have IIH. Although there is insufficient literature to generate an evidence-based management strategy for IIH, experienced clinicians can manage it well.

AN APPROACH TO PAPILLOEDEMA

Patients generally present to the emergency department after an optometrist or family doctor detects papilloedema. They may or may not have other symptoms. Because papilloedema indicates potentially serious underlying disease, the purpose of the visit is to recognise and confirm the presence of papilloedema and arrange appropriate onward investigation. An important issue is that, in the UK, the most junior and inexperienced doctor often assesses the patient first to confirm the clinical finding of papilloedema. Once
Recognising papilloedema is usually straightforward and the pathway of investigations moves forward. Having identified papilloedema, it is essential to record blood pressure to exclude malignant hypertension. Patients then need urgent neuroimaging: this has two purposes, to identify any space-occupying lesion and to exclude a venous sinus thrombosis. The preferred imaging method is an MR scan of the head and orbits with intravenous contrast and MR venogram; these should, ideally, include fat suppression sequences, as these better define the intraorbital optic nerves. However, if this is not readily available, a CT head scan with a CT venogram will exclude most.
space-occupying lesions, cerebral venous sinus thrombosis and Chiari malformation. There are several possible radiological signs of IIH, although none is pathognomonic (figure 8). There may be an empty sella, a partially empty sella, decreased pituitary height or transverse sinus narrowing. In the orbits, the optic nerve sheath complex may be enlarged, the posterior globe flattened and occasionally the optic nerve head protruded.¹

After excluding a structural intracranial lesion, patients require a lumbar puncture, performed with the patient in the lateral decubitus position. The opening pressure is important, so every effort should be made to ensure all equipment is at hand; this includes having more than one packet of manometer tubes to avoid being unable to measure a pressure >40 cm CSF. The patient must be comfortable, as Valsalva, talking, crying and flexed legs compressing an obese abdomen, may artificially raise the pressure reading. We suggest slightly straightening the patient’s legs at the hips to avoid compressing the intra-abdominal cavity. The column of CSF in the manometer needs sufficient time to settle—there should be small oscillations with breathing—before recording the reading. Our review on a practical

---

Figure 1  Single colour fundus photographs of patients with disc swelling secondary to raised intracranial pressure (papilloedema). (A) Mild papilloedema with burring and elevation of nasal disc margin (arrow). (B) Moderate papilloedema with obscuration of vessels by oedematous nerve fibre layer. (C, D, E) Severe papilloedema with cotton wool spots, nerve fibre layer haemorrhage (arrows C and D) and venous engorgement and tortuosity (arrow E). (F) Papilloedema with secondary optic atrophy. Note, as atrophy progresses, fewer nerve fibres can swell.
approach to lumbar puncture has more tips.\textsuperscript{5} Despite optimising the conditions for lumbar puncture, it is still a one-off reading. CSF pressure varies diurnally, so a snapshot recording is not the whole story. It is, however, useful retrospectively to ask the patient if their symptoms (obstructions, headache, etc) improved for a few days after the lumbar puncture. Confirming a temporary improvement supports there being raised intracranial pressure. If the lumbar puncture is technically challenging, fluoroscopic or ultrasound guidance may help. A CSF sample should be sent for microscopy, protein and glucose (and sometimes for xanthochromia and culture to identify secondary causes of raised intracranial pressure, such as CSF hypercellularity, eg, subarachnoid haemorrhage and meningitis). Patients should also have blood taken to exclude anaemia,\textsuperscript{6} to check serum calcium, plasma glucose and renal function.

There is some debate about the limits of normal lumbar CSF opening pressure. Whiteley \textit{et al}’s clinical study found the normal range for lumbar CSF opening pressure was 10–25 cm CSF (95\% reference interval); but some normal subjects had opening pressures of up to 28 cm CSF.\textsuperscript{7} Furthermore, there is only a weak, non-significant relationship between Body Mass Index and lumbar puncture opening pressure.\textsuperscript{7} In our experience, a common mistake is putting too much emphasis on a single reading, as normal people may have artificially high or low CSF pressures. When the clinical findings are out of keeping with the opening pressure, the pressure should be questioned and, in some cases, the lumbar puncture repeated. Occasionally, a CSF infusion study can help. However, we would recommend that all patients being evaluated for IIH whose lumbar pressure is $\geq 25$ cm CSF should see an experienced neurologist or ophthalmologist to weigh up the evidence towards a diagnosis of IIH.

Children with IIH often present differently to adults, although this is beyond the scope of this article. In other atypical cases, such as non-obese women or men, where there is no underlying systemic cause for raised intracranial pressure (see differential diagnosis), we suggest extracranial imaging to exclude pathology, such as internal jugular vein obstruction.

\textbf{DIFFERENTIAL DIAGNOSIS}

When there is papilloedema with symptoms and signs of raised intracranial pressure, it is important to obtain a thorough past history and system screen to

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure2.png}
\caption{Single colour fundus photographs of pseudopapilloedema in patients initially thought to have IIH. (A) Elevated, lumpy disc with anomalous vascular pattern including trifurcation of central retinal artery (arrow) seen in optic nerve drusen. (B) Small disc height (arrow) leads to a crowded appearance of the optic nerve without a physiological cup. (C and D) High magnification photographs of right and left eyes of a patient with anomalous discs which show the indistinct nasal disc margin (arrow C) and absent physiological cup (arrow D).}
\end{figure}
identify treatable causes (box 2). Polycystic ovarian syndrome has a comorbid association with IIH, but current evidence suggests that it does not raise intracranial pressure.8

A comprehensive drug history is essential (table 2). Tetracyclines, nitrofurantoin and excessive vitamin A intake frequently appear in case reports as raising intracranial pressure, and their withdrawal often resolves the problem. It is possible that the previous use of high-dose oestrogen oral contraceptives may also contribute. This has been difficult to investigate as many cases are women of childbearing age, and therefore there is a high incidence of the use of these medications in this age/sex group. If there is a strong temporal relationship between the oral contraceptive pill use and the diagnosis of IIH we may suggest stopping it. There is no evidence base here, but our practice is to suggest switching to a progesterone pill or barrier method. This requires careful management to avoid unplanned pregnancies. For patients with IIH wanting to start the oral contraceptive pill, we typically arrange more frequent review after starting it, but rarely note any problems.

Table 1  Mandatory visual function measurements

<table>
<thead>
<tr>
<th>Visual acuity</th>
<th>Test each eye separately for the best corrected (with glasses) distance visual acuity, using either Snellen’s or logMar chart. Use a pinhole to record improvement after correcting for refractive error.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colour vision</td>
<td>Test each eye individually with pseudoisochromatic plates, such as Ishihara’s plates.</td>
</tr>
<tr>
<td>Pupil examination</td>
<td>To exclude a relative afferent pupillary defect and oculosympathetic palsy (Horner’s syndrome).</td>
</tr>
<tr>
<td>Visual field assessment</td>
<td>Assess visual fields (either a Humphrey’s or Goldmann’s), as confrontational visual fields picks up only gross defects.</td>
</tr>
<tr>
<td>Dilated fundus examination</td>
<td>Document optic nerve head AND macular findings. This is important to exclude intraocular inflammation causing bilateral disc oedema. Ideally assess using a slit lamp.</td>
</tr>
</tbody>
</table>

Figure 3  Case one: (A and B) Right and left colour fundus photographs of the optic nerve head showing small crowded discs with anomalous branching of the blood vessels. (C and D) Left and right grey-scale plot taken from the Humphrey visual field test printout, showing the ‘clover leaf’ pattern of an unreliable test performance.

Figure 4  Surface and buried optic nerve head drusen. The disc is elevated and lumpy with visible whitish deposits (drusen) within the optic nerve head. Note the absence of the physiological cup and anomalous vascular branching (arrow).
MONITORING IN IIH

Routine clinical observation involves monitoring of the visual function (table 1). Clinicians often ask what is the best technique for monitoring visual fields: at our unit, we use Humphrey visual fields as in Case 1, and Goldmann visual fields as in case 2. Patients need serial visual fields, and it is best to use the same form of perimetry each time. We prefer Humphrey in those patients capable of concentrating and completing the tests as it is sensitive and reproducible. However, it is important not to interpret a field based entirely on the grey-scale plot, and to consider the reliability indices (fixation losses, false positives and false negatives). A patient with inattention, or poor compliance with the test, may show a dramatic visual field deficit, as in Case 1, often with a high false-negative rate.

Goldmann visual fields can be performed on manual and automated machines. Typically, the periphery is plotted using a kinetic (moving) target, and the central visual field is tested statically. Manual perimetry using a Haag–Streit Goldmann perimeter requires a skilled operator; it is useful for neuro patients with serious visual loss, or those needing significant supervision and encouragement to produce a reliable visual field. We find that non-organic visual loss is common in IIH, and so it is important to have a skilled operator who has time allowed for the patient.

Direct imaging of the optic nerve head is also useful in objectively assessing and longitudinally monitoring papilloedema and where there is fluid tracking to the macula. Colour fundus photography is an excellent way to record the fundal findings. Optical coherence tomography is becoming a superior technique, as it can measure swelling at the optic nerve head and the macula. Optical coherence tomography is very quick with the spectral (or Fourier) domain scan rate of at least 20,000 axial scans per second. It is non-invasive and provides high-resolution images with an axial resolution of 3–5 μm. Ultrasonographic B-scanning can also measure the optic disc height and the presence of excessive fluid within the optic nerve sheath (a surrogate marker of papilloedema).

MANAGEMENT

Disease evolution and outcomes in IIH are poorly characterised and are currently being evaluated in the National IIH: LIFE study (centres interested in participating should contact the author, AS). We have noted the following patient types:

▸ Those who rapidly lose vision at diagnosis over days to weeks (rare but vital to identify early).
▸ Those whose disease resolves following diagnosis, over weeks to months, occasionally after a single lumbar puncture (rare).
▸ Those at lower risk of visual loss who develop chronic disease with small fluctuations in disease activity, frequently with weight changes (the majority).
▸ Those in disease remission and off treatment.

For most patients, the clinical priority is to monitor vision and help the disease into remission. The headache symptoms typically comprise the greatest morbidity for these patients (see later). For patients in remission (the fourth cohort) with no papilloedema noted on visits over several years, we will aim to discharge and advise annual optometrist assessments, but return if any symptoms recur.

Management of acute visual loss in IIH

In high-risk patients with impending visual loss, some form of CSF divergence can be sight-saving. If the surgical procedure is likely to be delayed for 24–48 h, it is possible to insert a lumbar drain at the time of the lumbar puncture. The type of procedure depends on the local expertise and the neurosurgeon’s preference. The clear immediate benefit is preserved vision, and sometimes reversal of visual loss (Case 2). Options include a lumbarperitoneal shunt, where a catheter is inserted into the subarachnoid space at the lumbar spine between two vertebrae and fed around the oblique muscles under the skin into the peritoneum.
Figure 7  Fundus fluorescein angiography of the left eye with papilloedema. A rapid series of fundus photographs follow the intravenous injection of a fluorescent contrast agent. In true disc swelling, the frames (A–E) show progressively increased intensity and area of fluorescence at the disc. This shows fluorescein leakage from the oedematous disc.

Figure 8  (A) MRI T1-weighted sagittal image showing a partially empty sella. (B) MRI T2-weighted coronal imaging showing increased fluid in the optic nerve sheath complex bilaterally. (C) MRI T1-weighted axial image showing flattening of the posterior globes, and dilated optic nerve sheaths in patient with raised intracranial pressure.
Operatively (68% at 6 months and 79% at 2 years).9 We almost never recommend shunting exclusively to save vision in those at risk of imminent visual loss. Additionally, postoperative low-pressure headache occurs in one-third need multiple revisions, and one-third need shunt revision, and one-third need multiple revisions.9 We use shunting as a temporary measure to save vision in those at risk of impeding visual loss. While the shunt is working, we advise weight reduction to put their disease into remission. Additionally, we almost never recommend shunting exclusively to treat headache, as this continues in most patients postoperatively (68% at 6 months and 79% at 2 years).9 Also, postoperative low-pressure headache occurs in 28%.9 We recommend using shunts with a valve system and CSF reservoir to reduce the morbidity from over-drainage and under-drainage.

Optic nerve sheath fenestration is an alternative for protecting the vision; however, it has little effect on the overall intracranial pressure and can lead to visual loss in inexperienced hands.

Case 2
A 24-year-old woman presented with increasing blurring and ‘greying’ out of her left eye vision, particularly when bending over. She had a 3-week history of new onset headache, present on waking and of increasing severity. She reported a loud ‘whooshing’ noise in her left ear in the previous week. She had been previously well and her Body Mass Index was 34 kg/m². Visual acuity was 6/18 (right) and 1/60 (left). There was reduced colour vision in the left, with a relative afferent pupillary defect. There was extensive visual field loss in the left eye (figure 9). Her MR scan of brain and MR cerebral venogram were normal. The lumbar puncture opening pressure was 90 cm CSF, with normal constituents. She underwent a lumbar peritoneal shunt within 24 hours of presentation. Her vision returned to 6/9 in both eyes, and her immediate postoperative fields were markedly improved.

Conservative management
Weight loss
Some patients volunteer recent weight gain before presentation, others do not, but weight loss is currently the only proven disease-modifying treatment for all overweight patients.10 11 Our recent prospective study highlighted that a 15% reduction of body weight, using a low calorie meal replacement liquid diet for 3 months, significantly reduced intracranial pressure, papilloedema and headaches.10 However, strategies to achieve long-term significant weight loss are notoriously difficult with typically as little as 2–4 kg of weight loss maintained at 2 years irrespective of the diet followed.12 Many case reports describe the benefits of bariatric surgery in IIH.13 We are currently recruiting to a randomised controlled trial comparing efficacy and cost-effectiveness of the most effective community weight loss programme14 versus bariatric surgery.

Pharmacological management
Carbonic anhydrase inhibitors, such as acetazolamide, can provide symptomatic relief of raised intracranial pressure, although there is no evidence to support their benefit. Additionally, in the only randomised controlled trial looking at acetazolamide, over half the patients in the acetazolamide arm stopped treatment due to side effects.15 This aligns with our clinical experience that many cannot tolerate it. For these reasons, we manage many of our patients with active IIH without acetazolamide. The maximum dose is up to 2 g daily; in our experience, up to 1 g daily is adequate, depending on body weight. If we do prescribe acetazolamide, we use the modified release preparation to reduce side effects.

Managing venous stenoses
Many patients with pseudotumour cerebri have venous sinus stenosis (narrowing), particularly of the transverse sinuses, reflecting elevated intracranial pressure.16

We tend to avoid this in patients with low-lying cerebellar tonsils, as there is an increased risk of tonsillar descent following the shunt, with subsequent disabling cough headaches. A ventriculoperitoneal shunt diverts CSF from the lateral ventricle to the peritoneum. Less commonly, a ventriculointerstitial shunt can divert CSF from the lateral ventricle to the atrium of the heart, or a ventriculopleural shunt diverts it to the pleural cavity. The surgical risks include shunt malfunction, infection and over-drainage. Over half the patients need shunt revision, and one-third need multiple revisions.9 We use shunting as a temporary measure to put their disease into remission. Additionally, optic nerve sheath fenestration is an alternative for protecting the vision; however, it has little effect on the overall intracranial pressure and can lead to visual loss in inexperienced hands.

Table 2 Drugs associated with pseudotumour cerebri

<table>
<thead>
<tr>
<th>Tetracycline/minocycline/doxycycline</th>
<th>Corticosteroids (and withdrawal)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitrofurantoin</td>
<td>Beclometasone</td>
</tr>
<tr>
<td>Sulphonamides, for example, trimethoprim</td>
<td>Cimetidine</td>
</tr>
<tr>
<td>Nalidixic acid</td>
<td>Lithium</td>
</tr>
<tr>
<td>Vitamin A excess and retinoids</td>
<td>Tamoxifen</td>
</tr>
<tr>
<td>Depo Provera</td>
<td>Ciclosporin</td>
</tr>
<tr>
<td>Combined oral contraceptive pill</td>
<td>Non-steroidal anti-inflammatory drugs</td>
</tr>
</tbody>
</table>

Secondary causes of raised intracranial pressure.
Venous sinus thrombosis.
Anaemia.
Obstructive sleep apnoea.
Drug-related.
CSF hyperproteinemia/hypercellularity, for example, spinal cord tumour/meningitis/Guillain–Barré syndrome/subarachnoid haemorrhage.
Renal failure.
Endocrine diseases, for example, Addison’s/Cushing’s/hypothyroidism.

Box 2 Secondary causes of raised intracranial pressure for exclusion to diagnose IIH

▸ Secondary causes of raised intracranial pressure.
▸ Venous sinus thrombosis.
▸ Anaemia.
▸ Obstructive sleep apnoea.
▸ Drug-related.
▸ CSF hyperproteinemia/hypercellularity, for example, spinal cord tumour/meningitis/Guillain–Barré syndrome/subarachnoid haemorrhage.
▸ Renal failure.
▸ Endocrine diseases, for example, Addison’s/Cushing’s/hypothyroidism.

Several research centres are now evaluating the therapeutic potential of stenting the transverse sinus in IIH.\textsuperscript{17–20} There is growing consensus that the stents do not treat the underlying cause of IIH. Reducing intracranial pressure by lumbar puncture can resolve the stenoses.\textsuperscript{21} Stenting the stenoses may, however, improve IIH by increasing CSF drainage at the arachnoid granulations, thereby lowering intracranial pressure and improving the signs and symptoms of IIH.\textsuperscript{17–20} Serious complications of the procedure (venous sinus perforation, stent migration, in-stent thrombosis, subdural haemorrhage and the development of recurrent stenoses immediately proximal to the stent) suggest the need for caution with this approach.\textsuperscript{17–19} We need larger long-term randomised clinical trials to evaluate this treatment before it can become routine clinical practice.\textsuperscript{22}

Managing the headache

The priority for patients with chronic IIH is usually the control of disabling headaches. IIH headache characteristics are very variable. Many do not have the classical features of IIH headache described by the International Headache Society\textsuperscript{23} (progressive, daily, diffuse, non-pulsatile headache with aggravation by coughing or straining).\textsuperscript{24} We note that pressure features, such as aggravation with Valsalva or cough and severity worse in the morning (having been recumbent in the night) often do not occur, particularly as the condition becomes more chronic. The headaches typically alter during the course of the disease. In keeping with the literature, we find that headaches are often multifactorial, either due to raised intracranial pressure, low pressure, medication overuse headache, migraine or a combination of these.\textsuperscript{25–27} Migrainous features are particularly common (>70% of patients).\textsuperscript{28} Our practice, particularly in those in whom headache is the principal complaint, is to evaluate the headache phenotype fully and to focus treatment towards the principal headache type. Those with chronic burnt-out disease—typically with stable vision and no or minimal papilloedema—often have the greatest headache disability. There is little evidence base to guide headache management in IIH. We look for, educate about, and treat the frequent situation of medication overuse in IIH. We successfully use topiramate—a migraine prophylactic agent with weak carbonic anhydrase inhibitor activity and an appetite suppressant (in about 10%),\textsuperscript{29}—to treat headache in IIH. Amitriptyline also helps to reduce the impact of migrainous headaches. A headache diary is very useful, not just to quantify the headache load, but also for the patient.

![Figure 9](image_url) Case 2—Urgent CSF diversion surgery restored visual function. (A, B) Goldmann visual fields before and (C, D) after lumbar peritoneal shunt (left and right). (A) The left eye has an extensive visual field deficit and visual acuity of 1/60, the field is plotted (in green) only to the largest, brightest target called V4e (arrow). The patient was not able to perceive the smaller/ dimmer targets plotted in red, blue and black in figures 9B–D. (B) The right eye has an enlarged blind spot and reduced sensitivity of the visual field and visual acuity 6/18. (C and D) Left and right eye following the shunt show improved visual field and vision to 6/9 in both eyes.
Managing IIH without papilloedema. These patients typically have chronic headaches, and in some their phenotype (obesity and female sex) or symptoms of pulsatile tinnitus prompt a lumbar puncture with pressure measurement. It is not clear if IIH without papilloedema is a distinct pathological entity and there is debate as to whether these patients represent just chronic daily headache with a coincidentally elevated intracranial pressure. Pressures in these patients tend to be significantly lower than in typical IIH. Friedman et al has suggested that the diagnosis of IIH without papilloedema should only be made in those with a unilateral or bilateral sixth nerve palsy that also fulfil the criteria B-E dema should only be made in those with a unilateral or bilateral sixth nerve palsy that also fulfil the criteria B-E in association with at least three imaging findings suggesting raised intracranial pressure (empty sella, flattened posterior aspect of the globe, distended perioptic subarachnoid space ± a tortuous optic nerve and transverse sinus stenosis). These criteria may be too stringent and lead to the under-identification of cases. Sixth nerve palsies are uncommon, even in cases with frank papilloedema. As these patients do not have (and do not seem to develop) papilloedema, they do not tend to develop visual loss, although they may develop functional visual loss. Management focuses on treating the headache, and we use prophylactic and abortive agents appropriate for the headache phenotype.

Managing IIH in pregnancy

As IIH is common in women of childbearing age, there will inevitably be patients diagnosed with IIH who become pregnant. If the patient takes acetazolamide, we advise her to stop this on becoming pregnant, to minimise the risk of toxicity, particularly in the first trimester. However, in a series of 50 patients treated with acetazolamide during the first trimester, there were no reported adverse outcomes for the pregnancy or the baby. We therefore occasionally consider using acetazolamide, particularly after the first trimester, following an informed discussion of the potential risks and benefits. During pregnancy, we increase observations and begin communication with the obstetric team; we advise that the mother increase observations and begin communication with the obstetric team; we advise that the mother increase observations and begin communication with the obstetric team; we advise that the mother increase observations and begin communication with the obstetric team; we advise that the mother increase observations and begin communication with the obstetric team; we advise that the mother increase observations and begin communication with the obstetric team; we advise that the mother increase observations and begin communication with the obstetric team; we advise that the mother increase observations and begin communication with the obstetric team. The Institute of Medicine recommended 5–9 kg weight gain during the pregnancy (0.22 kg/week in the second and third trimester) in those with a starting Body Mass Index of ≥30 kg/m². For the great majority, the IIH remains stable and they can have a normal vaginal delivery. Very occasionally, when there is compromised optic nerve function, we advise against a prolonged second stage of labour. Epidural and spinal anaesthetic during labour (even with a shunt in situ) can still go ahead. A few patients present with IIH for the first time during the first trimester. If they have visual compromise they may require temporising serial lumbar punctures, until they can undergo CSF diversion during their second trimester.

In the postpartum period, acetazolamide is probably safe for a breastfeeding baby. Only 0.06% of the dose of acetazolamide given to the mother is ingested by the child (less than 0.7% of the dose/kg body weight received by the mother); such a low dose is unlikely to harm the baby.

CONCLUSIONS

Patients presenting with papilloedema need careful evaluation and timely investigation. This is required to exclude all other causes of swollen optic nerves and raised intracranial pressure. IIH is a diagnosis of exclusion. Acute management depends on the immediate risk to vision. For most patients, this is a chronic condition associated with significant disability from headache. Disease-modifying therapy is weight loss. CSF shunting should be considered temporary. IIH requires a multidisciplinary approach involving ophthalmologists, neurologists and neurosurgeons. These patients are best managed in centres with expertise in IIH.

Practice points

▸ Distinguishing papilloedema from pseudopapilloedema is not always straightforward, and may require a senior ophthalmology opinion.
▸ Pseudotumour cerebri describes raised intracranial pressure and papilloedema in the absence of a space-occupying lesion and can be caused by several conditions (box 2). Idiopathic intracranial hypertension is a diagnosis of exclusion where NO cause can be found.
▸ A single lumbar puncture opening pressure reading can be misleading. Where the opening pressure is out of keeping with the clinical picture, the clinician should review the whole case.
▸ Monitoring of visual fields can be problematic in many patients who have functional overlay.
▸ Treat the patient. High-risk patients lose vision rapidly. Headaches may be multifactorial, and require specialist evaluation and treatment to reduce disability.

Contributors SM, KM, JB, AJ, TM, MB: article drafting, key concepts, revision and final approval of the manuscript. AS: article conception, design, drafting, revision and final approval of the manuscript.

Competing interests All authors declare that they have no proprietary or commercial interests in the subject matter. Dr Sinclair is funded by an NIHR Clinician Scientist Fellowship (NIHR-CS-011-028) and the Medical Research Council, UK (MR/K015184/1).

Provenance and peer review Commissioned; externally peer reviewed. This paper was reviewed by Brendan Davies, Birmingham, UK.
REFERENCES